Current Oncology Reports

, Volume 1, Issue 2, pp 173–178

Cyclooxygenase-2 as a target for prevention of colorectal cancer

  • Monica M. Bertagnolli
Article

DOI: 10.1007/s11912-999-0030-6

Cite this article as:
Bertagnolli, M.M. Curr Oncol Rep (1999) 1: 173. doi:10.1007/s11912-999-0030-6

Abstract

COX-2 is an isoenzyme of cyclooxygenase that is increased in response to growth factors, cytokines, and other mitogenic stimuli. Upregulation of COX-2 gene expression and functional activity is an early event in colorectal tumor formation. The long-term use of cyclooxygenase inhibitors, such as aspirin and nonsteroidal anti-inflammatory drugs, is associated with a decreased rate of colorectal tumors. This observation holds across a range of experimental models, from animal genetic tumor models to large epidemiologic studies of human sporadic colorectal cancer. Selective inhibitors of COX-2 were primarily developed to treat COX-2-related inflammation with minimal side effects. These drugs, however, may also provide safe, effective chemoprevention of colorectal neoplasia.

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Monica M. Bertagnolli
    • 1
  1. 1.Strang Cancer Prevention CenterNew YorkUSA